What Dextrose 10% Vioser Treats: Main Uses and Benefits

Dextrose 10% Vioser is commonly used to address two main areas: symptoms related to systemic imbalance and fluid/nutritional depletion. The solution is generally applied across clinical domains where additional symptomatic support is needed. It is commonly used for managing conditions such as acute symptomatic hypoglycemia, where symptoms related to neurological activity like confusion and tremor become disruptive; fluid volume depletion associated with acute conditions, such as vomiting or diarrhea; and acute caloric deprivation during periods of fasting.

This medication supports the process of blood glucose restoration and provides essential fluid, assisting with maintaining functional stability during acute episodes. It is generally applied in clinical settings that involve unstable symptom patterns, such as emergency care, postoperative recovery, and for critically ill adults or children.

“The primary purpose is to provide supportive relief and assist the patient during difficult episodes by easing distress when nutritional balance is compromised.”

This therapeutic support helps ease the overall symptom burden related to energy loss and dehydration.

Quick Fact: Relief for Systemic Imbalance Dextrose 10% Vioser provides supportive carbohydrate energy that helps conserve the body’s structural reserves, assisting with the physiological strain associated with periods of nutritional deficiency.

Regulatory References

1. DailyMed - NIH Label for Dextrose 10% Injection

Who Can and Cannot Use Dextrose 10% Vioser?

The population eligibility for Dextrose 10% Vioser (Dextrose 10% Injection) is strictly defined by regulatory documents, focusing on conditions that present metabolic or fluid imbalance risks.

Absolute Contraindications

This medicine must not be used in patients with clinically significant hyperglycemia (high blood sugar) or a known hypersensitivity to dextrose. It is also contraindicated in patients with existing intracranial or intraspinal hemorrhage or conditions of water excess (hyperhydration).

Restricted or Conditional Use

Use is allowed but requires heightened monitoring and caution for specific groups, including patients with diabetes mellitus, impaired renal function, or cardiac insufficiency (heart failure) due to the risk of fluid and solute overload. Patients at risk for hyponatremia and those who are severely undernourished also require careful administration.

Age and Physiological Status

Neonates, particularly low birth weight infants, are at an increased risk of severe metabolic instability and require strict glycemic control. For pregnant women, use is conditional, permitted only if clearly needed, with a caution regarding administration during labor potentially causing neonatal hypoglycemia.

Interactions with other medicines and products

The official regulatory profile for Dextrose 10% Injection focuses on documented interaction patterns related to fluid balance, glycemic control, and physical incompatibilities during administration.

Official Interaction Statements

Population-Specific Interaction Notes

Regulatory documents explicitly state that the risk associated with the hyponatremia interaction is officially heightened in specific patient populations, including pediatric patients, geriatric patients, and patients with pre-existing conditions such as cardiac or pulmonary failure or risk factors for SIADH.

No specific interaction with food, alcohol, or common herbal products is listed in the dedicated drug interaction sections of official regulatory labels. No data regarding CYP-mediated or transporter-based interactions are documented.

Dextrose, a D-glucose isomer, functions as a direct substrate for cellular energy production. Following intravenous administration, dextrose is distributed rapidly through the plasma and interstitial fluid. It serves as the primary biological target for the facilitative glucose transporter proteins (GLUTs), notably GLUT-1 on erythrocytes and the blood-brain barrier, and GLUT-4 in muscle and adipose tissue, when signaled by insulin. The interaction type is transport into the cell.

Intracellularly, glucose is immediately phosphorylated by hexokinase to glucose-6-phosphate, the initial step of the glycolysis pathway. This phosphorylation traps the molecule inside the cell and commits it to catabolism. The molecular pathway proceeds through ten enzymatic steps, ultimately yielding pyruvate, with a net production of two ATP molecules per glucose molecule. Under aerobic conditions, pyruvate enters the Krebs cycle (or citric acid cycle) within the mitochondria, leading to the electron transport chain and a substantially greater ATP synthesis via oxidative phosphorylation.

This continuous supply of substrate maintains the intracellular ATP/ADP ratio and supports membrane potential integrity. System-level physiological consequences include the maintenance of plasma glucose concentration and the provision of substrate for necessary brain and red blood cell metabolic activity, which rely almost exclusively on glucose for their energy needs.

How to Use Dextrose 10% Vioser: Administration Guidelines

Dextrose 10% Vioser is a sterile solution designated for Intravenous Infusion only. The use of this 10% concentration solution follows defined procedural standards for its delivery into the circulatory system.

Administration Scope

Resulting Procedural Structure

The administration of Dextrose 10% Vioser follows a protocol that begins with the visual inspection of the solution to ensure its clarity and integrity. The required IV route and the dosing limits define the standardized, metabolically managed delivery of fluid and carbohydrate. This protocol ensures the solution is only delivered directly into the circulatory system at a pace that is appropriate for the patient’s clinical need.

Recent Clinical Evidence Summary

Dextrose 10% Solution for Injection is a solution containing 10 grams of D-glucose (dextrose) per 100 milliliters of water. As a hypertonic solution (approximately 505 mOsmol/L), its primary clinical application is to replenish fluid and provide a source of carbohydrate calories intravenously.

Research has recently focused on its use in the acute management of hypoglycemia (low blood sugar), particularly in pre-hospital and emergency settings, often as an alternative to highly concentrated dextrose solutions.

Dextrose 10% in Hypoglycemia Management

Studies comparing 10% dextrose solution (D10) to 50% dextrose solution (D50) for the treatment of out-of-hospital hypoglycemia have reported favorable outcomes for D10 use. Key findings from observational studies and controlled trials include:

• Efficacy in Glucose Restoration: In clinical cohorts, the median blood glucose levels of patients with severe hypoglycemia were observed to rise to a target euglycemic range (e.g., 91 to 98 mg/dL) after the initial administration of D10.
• Reduced Glycemic Variability: Use of D10 was associated with less extreme fluctuations in blood glucose levels post-treatment compared to the use of D50, which may contribute to a decreased risk of subsequent hyperglycemia and associated complications.
• Repeat Dosing: In several studies, approximately 18% to 23% of patients treated with D10 required an additional dose due to persistent or recurrent low blood glucose, suggesting that some patients may need further monitoring and titration.

Safety Profile Considerations

Due to its lower concentration and osmolarity compared to D50, 10% dextrose solution is generally associated with a reduced theoretical risk of extravasation injury (damage if the solution leaks out of the vein) and vein irritation when administered peripherally. Studies reporting the feasibility and efficacy of D10 protocols have generally found no reports of adverse events or deaths related to its administration for hypoglycemia.

Key Studies & References

1. Identification of highly concentrated dextrose solution (50% dextrose) extravasation and treatment—a clinical report

Common questions about Dextrose 10% Vioser (FAQ)

Q: Is there a recommended maximum infusion rate for Dextrose 10% Vioser?

Official product information suggests a maximum rate to prevent glucose loss in the urine, often referenced as 0.5 grams per kilogram of body weight per hour. This rate is related to the body's metabolic limits in processing dextrose. The final rate of administration is determined by a healthcare professional based on the patient's specific needs and clinical assessment.

Q: Can Dextrose 10% Vioser be given through a central venous catheter instead of a peripheral IV?

The solution is designed to be safe for administration through a peripheral vein. However, official information states that using a central venous catheter may be considered if there is discomfort, irritation, or inflammation of the vein (phlebitis) at the peripheral administration site. The choice of the administration route is made by a healthcare provider.

Q: How does Dextrose 10% Vioser compare to D5W (5% Dextrose) for general use?

Official product information shows that Dextrose 10% provides a higher concentration of sugar and calories than the 5% solution. Dextrose 10% is classified as a hypertonic solution, meaning it has a higher concentration of solutes than blood plasma, while the 5% solution is typically considered isotonic. The choice between the two formulations is based on the patient's specific fluid and nutritional requirements.

Q: What are the compatibility restrictions when using Dextrose 10% Vioser as a diluent for other IV medications?

When Dextrose 10% is used for mixing with other medicines, official guidance requires that the additive's solubility and stability in the dextrose solution be confirmed. Additionally, it must be ensured that the pH (acidity level) of the Dextrose 10% Vioser is appropriate for the medicine being combined with it. This process helps ensure the safety and effectiveness of the final mixture.

How to Store and Dispose of Dextrose 10% Vioser

Storage and disposal instructions for Dextrose 10% Vioser are defined by official regulatory requirements to ensure product integrity.

Official Storage Requirements

Dextrose 10% solution must be stored at Controlled Room Temperature, generally 20 to 25 C (68 to 77 F). It is essential to protect the solution from freezing and to avoid excessive heat. The container is a single-dose container and must remain in its overpouch until immediately before use. Prior to administration, the solution must be visually inspected to ensure it is clear and the container's seal is intact.

Disposal and Stability

Solutions containing additives must be used promptly and not stored. Because the container is single-use, any unused portion of the product must be discarded after use. Disposal of unused or expired solution must be performed according to local procedures for medicinal product waste.